Results: The SARC-F score of the sarcopenia group was statistically significantly higher and the incidence of osteoporosis was higher in this group than the group without sarcopenia (p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: Our aim is to evaluate the association of serum matrix metalloproteinase (MMP2), tissue inhibitor of metalloproteinase (TIMP2) levels, MMP2/TIMP2 ratio, SARC-F with primary sarcopenia, and to investigate the coexistence of primary sarcopenia and osteoporosis in geriatric population.
📊
Key Findings & Data:Materials and Methods: A total of 80 geriatric patients (41 sarcopenic patients) were included in the study.
💡
Conclusion & Impact:Results: The SARC-F score of the sarcopenia group was statistically significantly higher and the incidence of osteoporosis was higher in this group than the group without sarcopenia (p
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Objective: Our aim is to evaluate the association of serum matrix metalloproteinase (MMP2), tissue inhibitor of metalloproteinase (TIMP2) levels, MMP2/TIMP2 ratio, SARC-F with primary sarcopenia, and to investigate the coexistence of primary sarcopenia and osteoporosis in geriatric population. Materials and Methods: A total of 80 geriatric patients (41 sarcopenic patients) were included in the study. Patients with secondary sarcopenia were excluded. By SARC-F questionnaire, patients who were at risk for sarcopenia were found as mentioned by EWGSOP2. Serum MMP2 and TIMP2 levels were analyzed by ELISA method. Dual energy X-ray absorptiometry (DEXA) was used for the diagnosis of osteoporosis. Results: The SARC-F score of the sarcopenia group was statistically significantly higher and the incidence of osteoporosis was higher in this group than the group without sarcopenia (p
🔖
Cite This Article
KANAT, B. B., YAVUZER, H., DÖVENTAŞ, A., ERDİNÇLER, D. S., SUZAN, V. (2022). Association of Primary Sarcopenia with Serum MMP2, TIMP2 Levels, and MMP2/TIMP2 Ratio. European journal of geriatrics and gerontology (Online), Cilt: 4 - Sayı: 2, 46–51. https://ajindex.com/articles/511196
Montero-Fernández N, Serra-Rexach JA. Role of exercise on sarcopenia in the elderly. Eur J Phys Rehabil Med 2013;49:131-143
Cruz-Jentoft AJ, Landi F, Topinková E, Michel JP. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care 2010;13:1-7
Greenlund LJ, Nair KS. Sarcopenia--consequences, mechanisms, and potential therapies. Mech Ageing Dev 2003;124:287-299
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31
Karasik D, Kiel DP. Genetics of the musculoskeletal system: a pleiotropic approach. J Bone Miner Res 2008;23:788‐802
Frost HM. Bone’s mechanostat: a 2003 update. Anat Rec A Discov Mol Cell Evol Biol 2003;275:1081-1101
Lluri G, Langlois GD, McClellan B, Soloway PD, Jaworski DM. Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates neuromuscular junction development via a beta1 integrin-mediated mechanism. J Neurobiol 2006;66:1365-1377
Chen X, Li Y. Role of matrix metalloproteinases in skeletal muscle: migration, differentiation, regeneration and fibrosis. Cell Adh Migr 2009;3:337-341
El Fahime E, Torrente Y, Caron NJ, Bresolin MD, Tremblay JP. In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity. Exp Cell Res 2000;258:279-287
Oh J, Takahashi R, Adachi E, Kondo S, Kuratomi S, Noma A, Alexander DB, Motoda H, Okada A, Seiki M, Itoh T, Itohara S, Takahashi C, Noda M. Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice. Oncogene 2004;23:5041-5048
Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014;25:2359-2381
Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, Croix ALA, McCloskey E, Mellstrom D, Melton LJ, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N. The use o